What we're reading, February 5, 2016: new legislation could expand the use of telehealth under Medicare; Massachusetts finds its physicians only screen for depression half the time; and Martin Shkreli pleads the Fifth during most of his testimony before Congress.
A senator from Hawaii has introduced legislation that would expand the use of telemedicine under Medicare and eliminate many of the current restrictions on reimbursement. Currently, to be reimbursed for telehealth under Medicare, patients must be located at certain sites in certain rural areas and only Medicare-defined physicians and practitioners can provide these services, according to Healthcare Informatics. The new legislation would expand the site for use and would make telehealth be a basic benefit in Medicare Advantage.
The US Preventive Services Task Force may now recommend that all adults are screened for depression, but there is a long way to go. The Boston Globe reported that in Massachusetts, primary care providers only ask patients if they are depressed or have other emotional problems just half the time. In comparison, these physicians earned much higher scores for screening patients who should be screened for colon cancer (81%) and screening diabetics for blood sugar problems (96%).
As probably should have been expected, during his testimony before members of Congress so-called “pharma bro” Martin Shkreli, the former CEO of Turing Pharmaceuticals, was of little help in the hearing. Shkreli mostly pled the Fifth and did not answer questions or smirked at comments from the members of the committee, STAT reported. After Shkreli, Turing’s chief commercial officer was more forthcoming with answers.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More